Hillary Clinton released a statement Wednesday calling the skyrocketing price of the EpiPen “the latest troubling example of a company taking advantage of its consumers.”
EpiPen auto-injectors are life-saving devices for people who have severe allergies that could lead to anaphylactic shock. While the drug contained in EpiPens is cheap, the device itself, which is designed to be user-friendly and immediately dispense the correct dosage of the drug, is exorbitantly expensive.
“Over the last several years, Mylan Pharmaceuticals has increased the price of EpiPens by more than 400%,” Clinton noted in the statement. “They’re now charging up to $600 for a two-EpiPen set that must be replaced every 12-18 months. This both increases out-of-pocket costs for families and first responders, and contributes to higher premiums for all Americans and their employers.”
The statement called the price hikes “outrageous.”
“I believe that our pharmaceutical and biotech industries can be an incredible source of American innovation, giving us revolutionary treatments for debilitating diseases,” Clinton said. “But it’s wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them.”
Clinton called on Mylan to “immediately reduce the price of EpiPens” and noted her plan to require pharmaceutical manufacturers to “prove that any additional costs are linked to additional patient benefits and better value.” Clinton said there was “no apparent justification” for the high price of EpiPens.
Full Content: Business Insider
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI